Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2019
Reporting Period: Specific event date (June 27, 2019)
Context: The filing discloses a Regulation FD event regarding the publication of a scientific article co-authored by the Company's Chief Scientific Officer, Dr. Mark Lowdell, in the peer-reviewed journal PLOS ONE.
Key Financial Metrics
This filing is a current report regarding a scientific publication and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The material event is the dissemination of scientific research findings.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release (Exhibit 99.1) to announce the publication of the article.
- Unusual Items: None reported in this filing.
- Risks and Contingencies: No specific risks or contingencies are detailed in this 8-K text beyond the standard disclosure that the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) to understand the specific scientific findings published in PLOS ONE.
- Confirm the role of Dr. Mark Lowdell as Chief Scientific Officer and his contribution to the study.
- Review subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.